Aligos therapeutics presents data from its liver disease programs at the european association for the study of the liver (easl) congress 2023

-presentations include a late breaking poster from an ongoing phase 1b study of alg-000184 demonstrating multi-log reductions in hbsag, dna, and rna levels in subjects dosed for up to 36 weeks-

ALGS Ratings Summary

ALGS Quant Ranking